Ellison, Murielle Marie,Li, Yue-Sheng,Belouski, Edward John,Hecht, Randy Ira,Michaels, Mark Leo,Xu, Jing,Hamburger, Agnes Eva,Sun, Jeonghoon
申请号：
NZ72407610
公开号：
NZ724076A
申请日:
2010.05.04
申请国别(地区):
NZ
年份:
2020
代理人:
摘要：
Disclosed the use of a polypeptide comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 39, wherein (i) the residue at position 98 is arginine； (ii) the residue at position 171 is glycine； and (iii) the residue at position 180 is glutamic acid, in the manufacture of a medicament for treating Nonalcoholic steatohepatitis (NASH) in a human patient in need thereof Further disclosed is an isolated fusion protein comprising: (a) an IgG constant domain； (b) a linker sequence fused to the IgG constant domain； and (c) an FGF21 mutant fused to the linker sequence and wherein the FGF21 mutant as described.
